Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD of CVL-936 in Healthy Subjects
NCT04232878Phase 1Terminated
- Sponsor
- Cerevel Therapeutics
- Start
- Dec 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cvl-936 in substance use disorder (SUD) (3 arms), sponsored by Cerevel Therapeutics. Primary endpoints: Treatment Emergent Adverse Events at 30 days, Electrocardiogram measures at 30 days and 6 more. Started Dec 2019; status: terminated.
02
Drugs
cvl-936
03
Conditions
substance use disorder (SUD)
Beyond the preview
Go deeper on NCT04232878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04232878.